Erlotinib
Erlotinib plus cisplatin-based chemoradiation promising for cervical cancer
March 11, 2014Treatment with epidermal growth factor receptor inhibitor erlotinib combined with cisplatin-based chemoradiation seems safe and effective for locally advanced cervical cancer, according to a study.
Erlotinib doesn't hurt but doesn't help standard head-and-neck therapy
March 19, 2013Adding erlotinib did not increase treatment toxicity in squamous cell carcinoma of the head and neck, but it also did not improve survival.
Targeted treatment of resistant cancer may improve progression-free survival with some drugs
December 19, 2012Pockets of resistant cancer can be treated with focused, targeted radiation while continuing chemotherapy with the targeted drugs crizotinib or erlotinib.
Veristrat predicts response but not survival benefit from NSCLC treatment
October 17, 2012The plasma test VeriStrat can predict response but not survival benefit from erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
New tool reveals individual tumor cell reactions to therapy
September 06, 2012Time-lapse imaging, analytical tools, and software are combined to provide a detailed picture of a single tumor cell's response to a cancer drug.
Study demonstrates cost-effectiveness of erlotinib treatment
March 31, 2010Erlotinib is a marginally cost-effective treatment for patients with advanced non-small cell lung cancer, according to the results of an economic analysis published in the Journal of the National Cancer Institute (2010;102(5):298-306).
Sign Up for Free e-newsletters
ONA Articles
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |